Recipharm and Exela have announced that they have entered into an exclusive strategic alliance. The alliance between the two contract development and manufacturing organisations (CDMOs) aims to enhance sterile manufacturing capabilities in the US. As part of the alliance, Recipharm will be able to take advantage of Exela’s state-of-the-art manufacturing plant in Lenoir, NC, US.

Tiziana Life Sciences, a biotechnology company developing immunomodulation therapies, announced that the National Institutes of Health (NIH),'s National Institute on Aging has awarded a $4m grant to Dr Howard Weiner as principal investigator at Brigham and Women’s Hospital to be the key research site to study nasal anti-cd3 for the treatment of alzheimer’s disease (ad).

Liquid biopsy company ANGLE plc has announced a partnership with NuProbe, a genomics and molecular diagnostics company, to utilise the latter’s pan-cancer next-generation sequencing (NGS) panel.

The European Microbiome Innovation for Health (EMIH) association and the Microbiome Therapeutics Innovation Group (MTIG) have announced a new collaborative agreement. The agreement seeks to advance microbiome drug development by improving collaboration between the two microbiome focused coalitions.

Santhera Pharma has announced the results of its LIONHEART study, which evaluated Vamorolone – a corticosteroid – and confirmed its action as a mineralcorticoid receptor antagonist (MRA).

Drug discovery company Cresset has announced the extension of its global collaboration with chemical and biological contract research organisation (cro) Enamine.

Orthopaedics branch of Johnson and Johnson Medtech, Depuy Synthes, has announced that their surgical robotics system velys active has received 501k clearance from the US Food and Drug Administration (FDA).

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development and co-commercialisation agreement – already investigating three dxd antibody drug conjugates (adcs) ‒ to include mk-6070.

AbbVie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline.

Merck (known as MSD outside the US and Canada) have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire cn201, a novel investigational clinical-stage bispecific antibody for the treatment of b-cell associated diseases.

Memorial Sloan Kettering (MSK) have paired with Absci corporation to develop and discover new novel therapeutics through the use of generative artificial intelligence (genAI).

NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study, which assessed Primec for the treatment of patients with amyotrophic lateral sclerosis (ALS).